Vaxcyte, Inc. (PCVX)
70.66
+5.64
(+8.68%)
USD |
NASDAQ |
Oct 09, 12:43
Vaxcyte Net Income (Quarterly) : -284.30M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -284.30M |
| March 31, 2026 | -320.62M |
| December 31, 2025 | -246.51M |
| September 30, 2025 | -212.83M |
| June 30, 2025 | -166.57M |
| March 31, 2025 | -140.72M |
| December 31, 2024 | -137.08M |
| September 30, 2024 | -103.12M |
| June 30, 2024 | -128.70M |
| March 31, 2024 | -95.02M |
| December 31, 2023 | -180.80M |
| September 30, 2023 | -92.66M |
| June 30, 2023 | -68.34M |
| March 31, 2023 | -60.46M |
| December 31, 2022 | -78.05M |
| Date | Value |
|---|---|
| September 30, 2022 | -57.92M |
| June 30, 2022 | -48.53M |
| March 31, 2022 | -38.99M |
| December 31, 2021 | -28.56M |
| September 30, 2021 | -26.62M |
| June 30, 2021 | -23.68M |
| March 31, 2021 | -21.22M |
| December 31, 2020 | -20.74M |
| September 30, 2020 | -21.02M |
| June 30, 2020 | -20.32M |
| March 31, 2020 | -27.14M |
| December 31, 2019 | -14.62M |
| September 30, 2019 | -11.32M |
| June 30, 2019 | -10.66M |
| March 31, 2019 | -13.67M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Moderna, Inc. | -782.00M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 284.30M |
| EPS Diluted (Quarterly) | -1.968 |
| Enterprise Value | 8.042B |
| Earnings Yield | -10.91% |
| Normalized Earnings Yield | -10.91 |